The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Atomoxetine (Strattera®) has been accepted for use in the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme. They recommend that the presence of symptoms that were pre-existing in childhood should be confirmed.
Ondansetron orodispersible films (Setofilm®) have been accepted for restricted use in nausea and vomiting associated with emetogenic chemotherapy and post-operative nausea and vomiting (PONV). The review notes that generic preparations of ondansetron are available at a lower cost than the proprietary products.
Sodium phenylbutyrate granules (Pheburane®) have been accepted for use as an adjunctive therapy in the chronic management of urea cycle disorders. It is noted that this product provides an alternative to sodium phenylbutyrate tablets at no additional cost but is more expensive than an existing brand of sodium phenylbutyrate granules.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.